GSK Expands RSV Vaccine Approval in Japan

GlaxoSmithKline (GB:GSK) has released an update.

GlaxoSmithKline has expanded the approval of its RSV vaccine, Arexvy, in Japan to include adults aged 50-59 at increased risk due to certain health conditions. This marks a significant step as Japan becomes the first country to approve the vaccine for this age group, following similar approvals in 35 countries including the US. The decision is backed by a global phase III trial showing consistent safety and immunogenicity in this demographic.

For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.